Halda Therapeutics has initiated a Phase 1/2 clinical trial of HLD-0915, pioneering a new class of cancer therapies called RIPTAC, in patients with metastatic castration-resistant prostate cancer.

Merck's Phase 3 HYPERION trial of Winrevair (sotatercept) for pulmonary arterial hypertension (PAH) is stopped early due to positive results from the ZENITH trial.

WashU Medicine researchers found only 1% of Alzheimer's patients treated with lecanemab experienced severe side effects requiring hospitalization, confirming clinical trial safety data in a real-world setting.

Teclistamab and talquetamab, bispecific antibodies, demonstrate efficacy in relapsed/refractory multiple myeloma by reducing soluble BCMA levels in responding patients.

A groundbreaking clinical trial led by Addenbrooke's Hospital demonstrates 100% three-year survival rate for patients with BRCA-mutated breast cancer when treated with olaparib plus chemotherapy before surgery.

A groundbreaking Phase 1 trial at Yale Cancer Center demonstrated successful anti-cancer immune responses in all nine patients with advanced kidney cancer using personalized therapeutic vaccines.

Corcept Therapeutics' dazucorilant did not meet the primary endpoint in the DAZALS Phase 2 trial for amyotrophic lateral sclerosis (ALS).

A landmark Phase 3 trial involving 889 colon cancer patients across six countries found that structured exercise programs reduced cancer recurrence and death risk by 28% and 37% respectively.

Epcoritamab-bysp achieved durable complete responses in patients with relapsed/refractory large B-cell lymphoma, with 96% of complete responders at 2 years maintaining remission at 3 years.

AbilityPharma's Phase I/IIa ENDOLUNG trial demonstrated that ibrilatazar combined with paclitaxel/carboplatin doubled overall survival from 12.3 to 22.5 months in patients with stage III/IV squamous non-small cell lung cancer.

Phase 3 TRuE-PN1 trial met all primary and secondary endpoints, with 44.6% of patients achieving significant itch reduction compared to 20.6% in the placebo group after 12 weeks of treatment.

A meta-analysis of phase 3 trials TROPiCS-02 and EVER-132-002 demonstrates sacituzumab govitecan significantly improves progression-free survival and overall survival in HR+/HER2- metastatic breast cancer compared to physician's choice treatment.

New clinical data reveals daridorexant effectively reduces wakefulness throughout the night while improving next-morning sleepiness and daytime functioning in patients with chronic insomnia disorder.

Merck's zilovertamab vedotin, combined with R-CHP, achieved a 100% complete response rate in previously untreated DLBCL patients in a Phase 2 trial.

A third of 97 patients with advanced multiple myeloma achieved complete remission lasting five years or more after receiving a single infusion of CAR-T immunotherapy developed by Legend Biotech.

ZEISS Medical Technology announced that its CLARUS 700 ultra-widefield fundus imaging camera has received National Medical Products Administration (NMPA) approval in China, expanding access to advanced retinal diagnostic capabilities.

Signify Bio secured an oversubscribed $15 million initial financing round led by Actium Group with participation from Gates Foundation Strategic Investment Fund, Danaher Ventures, Eli Lilly, and American Cancer Society's BrightEdge.

Dr. Reddy's Laboratories and Alvotech have entered a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar version of Keytruda (pembrolizumab) for global markets.

Cleveland Clinic-led clinical trial demonstrates lorundrostat, an aldosterone synthase inhibitor, reduced systolic blood pressure by 8 points more than placebo in patients with uncontrolled hypertension.

Distalmotion has received FDA 510(k) clearance for its DEXTER Robotic Surgery System to perform adult cholecystectomy procedures, marking the second approved indication in the US following inguinal hernia repair clearance in Q4 2024.